What is a stock summary page? Click here for an overview.
Business Description
OBI Pharma Inc
ISIN : TW0004174008
Description
OBI Pharma Inc is a clinical-stage oncology company. It focuses on research and development for cancer therapies and aims to develop ground-breaking drugs. The core value lies in its passion to develop and deliver a portfolio of antibody-drug conjugates (ADCs) drugs for patients, in addition to its Globo H active immunotherapy. Its portfolio includes a spectrum of cancer targets, such as TROP2, Nectin-4, HER2, and other potential targets. These ADCs are built based on two distinct ADC technology platforms, with different characteristics. It offers a plug-and-play advantage through a specialized site-specific conjugation using a proprietary enzyme. Its segments are the anti-cancer new drug; bispecific monoclonal antibody new drug; botulinum toxin new drug; and CDMO segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.2 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 8.99 | |||||
| Beneish M-Score | -2.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 41.8 | |||||
| 3-Year EBITDA Growth Rate | -8.4 | |||||
| 3-Year EPS without NRI Growth Rate | -8.9 | |||||
| 3-Year FCF Growth Rate | -8.5 | |||||
| 3-Year Book Growth Rate | 2.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 13.04 | |||||
| 9-Day RSI | 19.5 | |||||
| 14-Day RSI | 24.54 | |||||
| 6-1 Month Momentum % | -15.14 | |||||
| 12-1 Month Momentum % | -9.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.34 | |||||
| Quick Ratio | 8.27 | |||||
| Cash Ratio | 7.59 | |||||
| Days Inventory | 71.73 | |||||
| Days Sales Outstanding | 31.63 | |||||
| Days Payable | 4.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.2 | |||||
| Shareholder Yield % | -14.18 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -121.69 | |||||
| Operating Margin % | -3783.67 | |||||
| Net Margin % | -3685.55 | |||||
| FCF Margin % | -3116.04 | |||||
| ROE % | -71.52 | |||||
| ROA % | -46.53 | |||||
| ROIC % | -92.26 | |||||
| 3-Year ROIIC % | -108.89 | |||||
| ROC (Joel Greenblatt) % | -178.36 | |||||
| ROCE % | -52.16 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 191.85 | |||||
| PB Ratio | 3.53 | |||||
| Price-to-Tangible-Book | 3.23 | |||||
| EV-to-EBIT | -4.22 | |||||
| EV-to-EBITDA | -4.65 | |||||
| EV-to-Revenue | 167.57 | |||||
| EV-to-FCF | -7.52 | |||||
| Price-to-GF-Value | 0.14 | |||||
| Price-to-Net-Current-Asset-Value | 7.57 | |||||
| Price-to-Net-Cash | 9.39 | |||||
| Earnings Yield (Greenblatt) % | -23.65 | |||||
| FCF Yield % | -16.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OBI Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 62.678 | ||
| EPS (TTM) (NT$) | -9.901 | ||
| Beta | -0.07 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 55.09 | ||
| 14-Day RSI | 24.54 | ||
| 14-Day ATR (NT$) | 2.472148 | ||
| 20-Day SMA (NT$) | 58.79 | ||
| 12-1 Month Momentum % | -9.17 | ||
| 52-Week Range (NT$) | 46.1 - 92.351061 | ||
| Shares Outstanding (Mil) | 262.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OBI Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OBI Pharma Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
OBI Pharma Inc Frequently Asked Questions
What is OBI Pharma Inc(ROCO:4174)'s stock price today?
The current price of ROCO:4174 is NT$46.10. The 52 week high of ROCO:4174 is NT$92.35 and 52 week low is NT$46.10.
When is next earnings date of OBI Pharma Inc(ROCO:4174)?
The next earnings date of OBI Pharma Inc(ROCO:4174) is .
Does OBI Pharma Inc(ROCO:4174) pay dividends? If so, how much?
OBI Pharma Inc(ROCO:4174) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers